TALEN-engineered human cell lines with microRNA-21 null mutations by Jessica Kurata, Ren-Jang Lin
RNA & DISEASE 2016; 3: e727. doi: 10.14800/rd.727; © 2016 by Jessica Kurata, et al. 
http://www.smartscitech.com/index.php/rd 
Page 1 of 4 
TALEN-engineered human cell lines with microRNA-21 null 
mutations 
Jessica Kurata, Ren-Jang Lin 
Department of Molecular and Cellular Biology and Irell & Manella Graduate School of Biological Sciences, Beckman Research 
Institute of the City of Hope, Duarte, California 91010, USA
Correspondence: Ren-Jang Lin 
E-mail: RLin@coh.org
Received: March 17, 2015
Published: March 29, 2016
Dysregulation of microRNA-21 (miR-21) is associated with many types of cancer as well as with kidney and 
cardiovascular diseases. Aberrant expression of miR-21 leads to multiple phenotypic alterations including 
cellular proliferation, invasiveness, apoptosis, and fibrosis. We recently used transcription activator-like effector 
nucleases to engineer human cell lines with miR-21 null mutations. As expected, loss of miR-21 resulted in 
decrease cell proliferation and reduced transforming activity in culture and in xenografts. Besides an increase of 
apoptotic gene expression, miR-21 knockout cells also had significantly increased expression of genes involved in 
extracellular matrix interaction. Results from small RNA sequencing suggest that miR-21 deletion changed the 
microRNA expression profile. These results raise intriguing possibilities that loss of miR-21 expression may 
influence cellular interactions and that cells with long term miR-21 deficiency may compensate for the loss of 
this highly expressed microRNA by changing the abundance of alternate microRNAs or the AGO2 protein in 
order to maintain the microRNA-AGO2 homeostasis. Further characterization and utilization of miR-21 
knockout human cells will shed new light on this pathologically important microRNA. 
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microRNA-21 in cancer and fibrotic disease 
MicroRNA-21 (miR-21) was one of the earliest 
discovered oncogenic microRNAs (oncomiRs) and is 
overexpressed in the majority of cancers [1]. Circulating 
miR-21 has the potential to be a diagnostic or prognostic 
marker for many of those cancers [2, 3], and miR-21 
overexpression is associated with drug resistance of cancer 
cells [4]. Though this miRNA was initially linked to cancer, 
further studies have revealed miR-21 to be associated with 
other pathological processes, including cardiovascular 
disease [5], kidney fibrosis [6], and wound healing [7]. MiR-21 
expression increases in cardiac fibroblasts during heart 
disease and an overexpression of miR-21 impairs the ability 
of the heart to contract [5, 8]. Up regulation of miR-21 in 
kidney fibrosis disrupts organ structure and contributes to the 
disease [6]. Recently, miR-21 was shown to play a different 
role by acting as an anti-inflammatory factor in macrophages 
[7]. The multitude of functions miR-21 can have in both 
disease and healthy states makes this miRNA intriguing to 
study.  
Due to miR-21’s importance for cancer and other diseases, 
there has been much effort to understand the function of this 
miRNA. Several direct targets of miR-21 have been 
characterized, including programmed cell death protein 4 
(PDCD4), phosphatase and tensin homolog (PTEN), sprout 
homolog 1 (SPRY1), and peroxisome proliferator-activated 
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receptor α (PPARα). Down regulation of PDCD4, a tumor 
suppressor and apoptotic factor, by miR-21 has been linked 
to cancer development and metastasis [9, 10]. Also identified 
as a miR-21 target in cancer, PTEN down regulation has 
been linked to increased cancer cell proliferation and motility 
[11]. In cardiac fibroblasts, miR-21 mediated down regulation 
of PTEN has been associated with increased matrix 
metalloproteinase expression and extracellular matrix defects 
[8]. SPRY1 down regulation has also been seen in cardiac 
fibroblasts, leading to decreased apoptosis of these fibrotic 
cells [5]. In the kidneys, miR-21 targeting of PPARα, not 
SPRY1, is thought to be the primary mediator of fibrosis [6]. 
Many other direct and indirect miR-21 targets have been 
reported [12] and there are likely more to be discovered. 
TALEN-mediated gene editing of microRNA-21 
The advent of novel sequence-specific gene editing 
techniques such as zinc finger nucleases, transcription 
activator-like effector nucleases (TALENs), and 
CRISPR/Cas9 nucleases have provided a mechanism by 
which new information about a gene can be discovered 
through precise editing of that gene. TALENs are 
recombinant proteins composed of a transcription 
activator-like (TAL) effector fused to FokI’s DNA cleavage 
domain [13-15]. TAL effectors are derived from DNA binding 
proteins secreted by the plant bacterium Xanthomonas [16] 
and composed of repeating units containing 34 to 35 amino 
acids in which only residues 12 and 13, called the 
repeat-variable diresidue (RVD), are different. The RVD 
sequence determines the affinity of each repeating unit for a 
specific DNA base-pair [17, 18]. TAL effectors can be 
engineered by ligating multiple repeating units together to 
bind at specific sites in the genome [14]. The other part of a 
TALEN is composed of the DNA cleavage domain of FokI 
[19]. FokI is a type II restriction endonuclease which only 
cleaves when in a dimer [20]. The necessity of dimer 
formation for cleavage give TALENs additional specificity, 
especially compared to the off-target prone CRISPR-Cas9 
system [21, 22], as a pair of TALENs must both bind DNA with 
appropriate spacing and orientation. These TALENs create 
DNA double strand breaks at specific sites and the repair of 
these sites by non-homologous end joining can result in a 
small deletion or insertion in the target gene [23]. Target gene 
knockout can also be achieved using two pairs of TALENs to 
cleave the DNA on either side of the target region and delete 
the sequence in between. 
Our group and others have designed and used TALENs to 
target the human microRNA-21 gene [23-26]. We performed 
TALEN-mediated knockout of miR-21 in HeLa cells using 
three TALEN pairs to remove or disrupt the stem-loop 
sequence containing miR-21 [25]. Single clones homozygous 
for miR-21 knockout were isolated. Phenotypic studies 
showed the complete knockout of miR-21 resulted in a 
decreased growth rate, decreased colony forming activity, 
and less transformed xenografts. The knockout also increased 
sensitivity of HeLa cells to the chemotheraputic cisplatin, 
which is consistent with conventional miR-21 knockdown 
studies [27]. To determine which gene expression changes 
were associated with these phenotypes, we examined the 
changes in expression of miR-21 target genes using 
RNA-seq. A significant enrichment of mRNAs important for 
cell adhesion, extracellular matrix (ECM), and integrin 
binding was detected. Surprisingly, although much focus has 
been placed on miR-21 as an anti-apoptotic factor, these 
ECM pathways are more highly enriched than apoptosis and 
cell death pathways. This indicates changes in interaction 
with the ECM may be more prevalent than increased 
apoptosis in cells with long term miR-21 deficiency.  
Potential microRNA-AGO2 rebalance resulted from the 
loss of the abundant miR-21 
The small RNA profile of our cells was examined to 
determine what changes in miRNA expression profile 
occurred after miR-21 knockout. We found 11 miRNAs 
significantly upregulated and 10 miRNAs significantly 
downregulated in both of our knockout lines. Interestingly, 
only one of these differentially expressed miRNAs, 
miR-487b, is also significantly changed when miR-21 is 
knocked out in HEK293 cells [24].The small overlap between 
the different cell lines indicates the change in miRNA profile 
in response to miR-21 knockout may be the result of missing 
an abundant miRNA, rather than removal of miR-21’s 
function. We hypothesize that the loss of an extremely highly 
expressed miRNA (in HeLa cells >50% of the total 
microRNA reads are of miR-21) could change the miRNA 
dynamics within the cell. The limiting factor in miRNA 
abundance is the availability of the AGO2 protein, which is 
necessary to prevent the degradation of miRNAs [15]. 
Reciprocally, a dependence of AGO2 on miRNA abundance 
for stability can be seen in mouse cells [28]. Since human 
AGO2 is able to bind non-miRNA small RNAs [29], the effect 
of miRNA abundance on human AGO2 stability is less clear. 
There are two possible mechanisms by which removal of a 
highly abundant microRNA could change global microRNA 
dynamics: 1) removal of miR-21 results in decreased total 
miRNA levels and decreased AGO2, 2) removal of miR-21 
results in increased stability of alternate miRNAs as more 
AGO2 is available for binding. To distinguish between these 
mechanisms, we have examined the AGO2 levels in miR-21 
knockout cells and detected a small decrease. However, 
additional experiments are needed to determine if there was 
an increase of alternate miRNAs or other small RNAs bound 
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to AGO2. To further examine the hypothesis, total miRNA 
abundance of wild type and miR-21 knockout cells will need 
to be determined. It remains challenging to obtain an 
accurate measurement of the total miRNA abundance in a 
cell. The use of Agilent’s small RNA tool for the 2100 
Bioanalyzer allows for quantification of total RNA from 
20-40 nts in length, but this method is highly sensitive to the 
variation in RNA quality and can overestimate the fraction of 
miRNAs [30]. A preferred method would be to spike a known 
quantity of a short RNA not found in human cells into the 
miRNA-seq samples and, with this internal standard, 
information about the changes in abundance of each miRNA 
after knockout may be obtained. Further work to determine 
how miRNA dynamics change in response to miRNA 
knockout will not only be important for miR-21, but also for 
siRNA and shRNA therapeutics as these also compete with 
microRNAs for AGO2 binding [31]. 
Due to the strong association of miR-21 with cancer and 
its function as an anti-apoptotic factor, miR-21 has become a 
drug development target [32]. For example, a miR-21 
targeting antisense oligonucleotide, RG-012, is currently 
under development by Regulus Therapeutics for use in 
treating Alport syndrome, a genetic disorder associated with 
kidney disease [33]. Our study, along with previously 
published data, show that miR-21 has multiple important 
roles in healthy and diseased human cells. This makes it 
necessary to carefully examine the possible side effects of 
miR-21 targeting drugs, especially as miR-21 is important 
for limiting inflammatory response [7]. Also, complications of 
long-term miR-21 treatment should be examined as miR-21 
knockout mice did not show the same decrease in cardiac 
fibrosis seen when miR-21 was knocked down by short term 
use of antisense lock nucleic acids (LNA) [34, 35]. Though it is 
possible this discrepancy is due to potential off-target effect 
associated with antisense nucleic acids, it is equally possible 
that an unidentified compensatory mechanism for long term 
loss of miR-21 may exist. This putative mechanism should 
be investigated before anti-miR-21 therapeutics can be 
effectively used to treat chronic conditions. It is therefore 
important to understand the potential inflammatory side 
effects of targeting this miRNA, as well as the resistance and 
other possible complications from long term down-regulation 
of miR-21. The use of new gene editing technologies, such as 
TALENs, allows for a deeper and comprehensive 
understanding of the role of miR-21 in human disease and 
treatment.  
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